Titlebook: Drug and Gene Delivery to the Central Nervous System for Neuroprotection; Nanotechnological Ad Hari S. Sharma,Dafin F. Muresanu,Aruna Sharm

補(bǔ)給線

書目名稱Drug and Gene Delivery to the Central Nervous System for Neuroprotection影響因子(影響力)




書目名稱Drug and Gene Delivery to the Central Nervous System for Neuroprotection影響因子(影響力)學(xué)科排名




書目名稱Drug and Gene Delivery to the Central Nervous System for Neuroprotection網(wǎng)絡(luò)公開(kāi)度




書目名稱Drug and Gene Delivery to the Central Nervous System for Neuroprotection網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書目名稱Drug and Gene Delivery to the Central Nervous System for Neuroprotection被引頻次




書目名稱Drug and Gene Delivery to the Central Nervous System for Neuroprotection被引頻次學(xué)科排名




書目名稱Drug and Gene Delivery to the Central Nervous System for Neuroprotection年度引用




書目名稱Drug and Gene Delivery to the Central Nervous System for Neuroprotection年度引用學(xué)科排名




書目名稱Drug and Gene Delivery to the Central Nervous System for Neuroprotection讀者反饋




書目名稱Drug and Gene Delivery to the Central Nervous System for Neuroprotection讀者反饋學(xué)科排名

險(xiǎn)代理人

MORPH

Nanotechnology Based Approaches for Neurodegenerative Disorders: Diagnosis and Treatment,zheimer’s disease (AD) and Parkinson’s disease (PD) represent the most common neurodegenerative disorders worldwide. The early diagnoses of AD and PD together with a successful treatment hampering the neurodegenerative process are priority objectives for the scientific community. Although new treatm

發(fā)出眩目光芒

異端邪說(shuō)2

Sleep Deprivation Induced Blood-Brain Barrier Breakdown and Brain Pathology. Neuroprotective Effectrts suggests that sound sleep for less than 4 h results in confusion, simple task calculations, and affects decision making. However, in military life SD of 12–72 h is quite common. It appears that longer duration of SD is related to brain dysfunction. Model experiments carried out in our laboratory

Mhc-Molecule

Mhc-Molecule

Viral Vector Gene Delivery to the Brain for Treating Neurogenetic Diseases,sed viral vectors, herpes simplex viruses (HSVs), lentiviruses (LVs) and adeno-associated viruses (AAVs) are described, as well as the potential routes of administration for delivery of viral vectors in humans. This chapter highlights the main neurogenetic diseases for which viral vector-based therapies are being developed.

保留

amygdala

聚集